Biotech Series B Investors & VC Firms
900 firms in this list, with a median first check of $550K. 188 of them lead rounds. Generated from verified public data and updated continuously.
Red Capital
TokyoPre-Seed–Growth
3 people
Zynext Ventures
PenningtonPre-Seed–Series B
3 people
Mohr Davidow Ventures
San MateoSeed–Late Stage$200K – $4M
5 people
Danen Capital
ShenzhenSeed–Growth
2 people
Global Health Investment Corporation
New YorkSeed–Series B
2 people
Nimble Ventures
San FranciscoSeed–Series B
2 people
Strategic Investment Partners Inc.
TokyoPre-Seed–Growth
2 people
Cathay Health
San FranciscoSeed–Late Stage
1 person
Syngenta Group Ventures
DurhamSeed–Growth$500K – $5M
5 people
BDC Life Sciences Venture Fund
MontrealPre-Seed–Growth
2 people
Schouten Investments
AmsterdamSeries B–Late Stage
2 people
KSP, Inc.
KawasakiPre-Seed–Growth
1 person
SBI Investment
TokyoPre-Seed–Growth$2M – $227M
1 person
Shinsei Capital Partners
TokyoPre-Seed–Late Stage
WING by Digital Wallonia
LiègePre-Seed–Growth
Aurum Ventures MKI
Ramat GanSeed–Late Stage
8 people
Trans-Pacific Technology Fund
TaipeiSeed–Late Stage
8 people
Volcanics Venture
ShanghaiSeed–Series B
8 people
Ambix Venture Management, Llc
Mountain ViewPre-Seed–Late Stage
2 people
Bridford Investments (Bridford Group)
LondonPre-Seed–Growth
2 people
Gilmartin Capital LLC
LarkspurSeries A–Late Stage
2 people
MB Venture Partners
MemphisPre-Seed–Late Stage
2 people
SENACYT
Panama CityPre-Seed–Growth$150K
2 people
StarChain Ventures
Silicon ValleyPre-Seed–Series B
2 people
Related lists
Series B Investors & VC Firms (4094)Biotech Investors & VC Firms (2107)Biotech Seed Investors & VC Firms (1754)Series B Investors & VC Firms in United States (1625)Biotech Series A Investors & VC Firms (1596)SaaS Series B Investors & VC Firms (1317)Series B Investors & VC Firms in Global (1265)Enterprise Software Series B Investors & VC Firms (1242)Healthtech Series B Investors & VC Firms (1216)Fintech Series B Investors & VC Firms (1141)
Data sourced from public filings and firms' own websites — see our methodology.
















